Does systems biology analysis reveal NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer?
We provide evidence that NFAT-signaling pathway activation could help to identify aggressive forms of BC and potentially be a guide to assignment of phenotype-specific therapeutic agents. The NFAT5 transcription factor might be developed into routine clinical practice as a putative biomarker of IBC phenotype.
Collectively, the present data indicate a functional role for EMR2 in the modulation of neutrophil activation during inflammation.